The latest multi-asset licensing and option agreement between Argos and Novartis, will grant the Swiss pharma giant rights to key siRNA molecules, building on the companies’ partnership.

This partnership will leverage BioDuro’s expertise and Atombeat’s in silico modeling know-how to launch an AI-powered platform that allows for accelerated development of next-generation peptides.

The companies will work together, leveraging Syntekabio’s AI prediction platform for virtual screening to uncover new, high-potential indications for MetaVia’s DA-1241 oral therapy.

The strategic collaboration will also provide GSK with an exclusive worldwide license for Hengrui’s potential best-in-class PDE3/4 inhibitor, which is in clinical development as an add-on maintenance treatment for COPD.

The strategic collaboration and license agreement is potentially worth more than USD 1 billion and offer patients less burdensome treatment regimens through sustained ocular delivery of therapies.

Through the exclusive option and license agreement, Novartis will fund Matchpoint’s research into oral covalent inhibitors and will have the option to exclusively develop and commercialize all products resulting from the collaboration.

The site in Ridgefield, N.J., will provide Thermo with additional U.S. drug product manufacturing capacity and will allow the company to meet the growing demand from pharma and biotech customers for U.S. drug product manufacturing.

Customers in Germany, France, Benelux, Poland, and the Nordics will be able to purchase the higher bulk density excipients, which are useful for those seeking to reduce tablet size, from Brenntag.

With this latest private transaction, Bain Capital, a private investment firm, joins PCI’s investor base of Kohlberg, Mubadala, and Partners Group, which are focused on supporting the company in its growth plans.

The partnership will see the integration of a real time glucose monitoring platform into a bioreactor range, eliminating the need for manual testing of nutrients and improving data resolution.

BioVersys and Shionogi are joining forces to progress the development of non-tuberculous mycobacteria clinical candidates with the potential for a selected number of molecules to be licensed for global commercialization.

The collaboration will leverage Bend’s expertise in controlled release formulation, manufacturing process, and analytical method development, and Starton’s deep understanding of continuous delivery of lenalidomide.

The companies will combine a drug discovery platform and a novel framework to reduce the cost and time it takes to develop complex therapies.

The proposed acquisition will expand Sanofi’s immunological portfolio with a precision medicine already approved for the treatment of ASM and ISM, a next-gen highly selective kinase inhibitor, and an investigational oral drug.

Porton Advanced has announced separate partnerships with TongEYE and Hualong Biological, as it moves into regenerative therapies for vision loss and innovative immunotherapies for solid tumors.

The court supervised purchase, which is still subject to relevant conditions, will see Regeneron acquire the assets of 23andMe, except for its Lemonaid Health business.

The acquisition of efimosfermin alfa, a Phase III-ready FGF21 analog targeting steatotic liver diseases, will expand GSK’s hepatology pipeline and establish a best-in-class therapy for MASH and ALD.

Through this sizable acquisition, Merck will accelerate its growth in the rare tumor segment and boost its U.S. oncology presence.

Pharmaceutical company, Granules India, has acquired Swiss CDMO, Senn Chemicals AG, for CHF 20 million (USD22 million) through its subsidiary, Granules Peptides as it enters the peptide therapeutics sector.

The radiopharmaceuticals CDMO will have a majority stake in Agilera Pharma, advancing its strategy of becoming a fully-integrated service provider in the radiopharmaceutical therapy sector.